A look at the portfolio of emerging classes of obesity medications in early development

Scheduled for:Oct 21, 2024 8:00 PM EDT

Call Duration:30 minutes

Desired Expert

Obesity specialty with recent clinical trial experience or KOL that has reviewed the latest phase 2 trials for GIPRa/GLP-1Ra, GLP1R-GCGR, Long-acting NPY2-receptor agonist, and GLP1/FGF21 compounds.

Interview Goal

Understand emerging classes of obesity drugs, including GIPRa/GLP-1Ra, GLP1R-GCGR, Long-acting NPY2-receptor agonist, and GLP1/FGF21 compounds.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.